• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• Twitter
• Newsletter

Advertisement

Organisation › Details

H. Lundbeck A/S

H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical company highly committed to improving the quality of life for people suffering from brain disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company's products are targeted at disorders such as depression and anxiety, schizophrenia, insomnia, epilepsy and Huntington's, Alzheimer's and Parkinson's diseases. Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark. Today Lundbeck employs approximately 5,900 people worldwide. Lundbeck is one of the world's leading pharmaceutical companies working with brain disorders. In 2010, the company's revenue was DKK 14.8 billion (approximately EUR 2.0 billion or USD 2.6 billion). *

 

	Start	1990-01-01 existent
	Group	Lundbeck (Group)
	Industry	pharmaceutical
	Industry 2	psychopharmaceutical
	Person	Dunsire, Deborah (Lundbeck 201809– CEO before XTuit Pharma + Forum/EnVivo Pharma + Millennium/Takeda)
	Person 2	Götzsche, Anders (Lundbeck 201309 CFO)
	Region	København (Copenhagen)
	Country	Denmark
	Street	9 Ottiliavej
	City	2500 Valby
	Tel	+45-3630-1311
		Address record changed: 2020-12-02
Basic data	Employees	G: 5,001 to 10,000 (2019-12-31)
	Currency	DKK
	Annual sales	17,036,000,000 (revenue, consolidated (2019) 2019-12-31)
	Profit	2,667,000,000 (2019-12-31)
	Cash	3,008,000,000 (2019-12-31)
		* Document for �About Section�:
		Record changed: 2022-04-08

Advertisement

More documents for Lundbeck (Group)

• [1] H. Lundbeck A/S. (4/8/22). "Press Release: Joerg Hornstein to Join Lundbeck as Chief Financial Officer and Head of Corporate Functions". Valby....
• [2] Lundbeckfonden. (4/4/22). "Press Release: Lundbeck Foundation Shifts into New Biotech Gear. New unit Raises Ambitions in Denmark – Lundbeckfonden BioCapital"....
• [3] H. Lundbeck A/S. (11/29/21). "Press Release: Lundbeck Announces Changes to Executive Management". Valby....
• [4] H. Lundbeck A/S. (3/27/20). "Press Release: Lundbeck Announces Phase IIa Study Results of Lu AG06466 in Adults with Tourette Syndrome". Valby....
• [5] CytomX Therapeutics, Inc.. (3/23/20). "Press Release: CytomX Therapeutics Announces Appointment of Carlos Campoy as Chief Financial Officer". South San Francisco, CA....
• [6] H. Lundbeck A/S. (10/22/19). "Press Release: Lundbeck Completes the Acquisition of Alder BioPharmaceuticals – a Company Committed to Transforming Migraine Treatment and Prevention". Valby....
• [7] H. Lundbeck A/S. (9/16/19). "Press Release: Lundbeck to Acquire Alder BioPharmaceuticals – a Company Committed to Transforming Migraine Treatment and Prevention – in a Transaction Valued at up to USD 1.95 Billion Net of Cash". Valby & Bothell, WA....
• [8] Athira Pharma, Inc.. (7/11/19). "Press Release: Athira Pharma Announces Appointment of Mark Litton as Chief Operating Officer"....
• [9] H. Lundbeck A/S. (5/29/19). "Press Release: Lundbeck Closes Acquisition of Abide Therapeutics". Valby....
• [10] H. Lundbeck A/S. (5/6/19). "Press Release: Lundbeck to Acquire Abide Therapeutics, Adding a Unique Discovery Platform and a Lead Compound in an Exploratory Phase IIa Program for Tourette’s". Valby & San Diego, CA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2022. Made in Germany.